Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell‐surface CXCR4 as a synergistic target for combinatorial therapy
BTKi are preferred in clinical practice over idelalisib due to lower toxicity, but idelalisib plus anti ‐ CD20 antibodies remains relevant in the treatment of CLL cases resistant to BTKi and vene-toclax, in BTKi ‐ intolerant patients, and next ‐ generation PI3Ki such as duvelisib or umbralisib are being developed.